199 related articles for article (PubMed ID: 36082606)
1. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.
Margot NA; Naik V; VanderVeen L; Anoshchenko O; Singh R; Dvory-Sobol H; Rhee MS; Callebaut C
J Infect Dis; 2022 Nov; 226(11):1985-1991. PubMed ID: 36082606
[TBL] [Abstract][Full Text] [Related]
2. Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.
Margot N; Pennetzdorfer N; Naik V; Rhee M; Callebaut C
Antivir Ther; 2023 Dec; 28(6):13596535231220754. PubMed ID: 38085652
[TBL] [Abstract][Full Text] [Related]
3. Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus.
Chatzidaki I; Curteis T; Luedke H; Mezzio DJ; Rhee MS; McArthur E; Eddowes LA
Value Health; 2023 Jun; 26(6):810-822. PubMed ID: 36566886
[TBL] [Abstract][Full Text] [Related]
4. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.
Tailor MW; Chahine EB; Koren D; Sherman EM
Ann Pharmacother; 2024 Feb; 58(2):185-195. PubMed ID: 37138515
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.
Margot N; Vanderveen L; Naik V; Ram R; Parvangada PC; Martin R; Rhee M; Callebaut C
J Antimicrob Chemother; 2022 Mar; 77(4):989-995. PubMed ID: 35028668
[TBL] [Abstract][Full Text] [Related]
6. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.
Prather C; Lee A; Yen C
Am J Health Syst Pharm; 2023 Dec; 80(24):1774-1780. PubMed ID: 37767713
[TBL] [Abstract][Full Text] [Related]
7. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.
Bester SM; Adu-Ampratwum D; Annamalai AS; Wei G; Briganti L; Murphy BC; Haney R; Fuchs JR; Kvaratskhelia M
mBio; 2022 Oct; 13(5):e0180422. PubMed ID: 36190128
[TBL] [Abstract][Full Text] [Related]
8. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus.
Lee NE; Sutherland RK
Curr Opin Infect Dis; 2023 Feb; 36(1):15-19. PubMed ID: 36753704
[TBL] [Abstract][Full Text] [Related]
9. Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.
Margot N; Ram R; Rhee M; Callebaut C
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288639
[TBL] [Abstract][Full Text] [Related]
10. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
[TBL] [Abstract][Full Text] [Related]
11. Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS
Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187
[TBL] [Abstract][Full Text] [Related]
12. Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF
Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807
[TBL] [Abstract][Full Text] [Related]
13. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.
Dzinamarira T; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Alsharif A; Khan A; Kamal M; Rabaan AA; Alfaraj AH; AlShehail BM; Alotaibi N; AlShehail SM; Imran M
Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374245
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.
Nka AD; Bouba Y; Teto G; Semengue ENJ; Takou DK; Ngueko AMK; Fabeni L; Carioti L; Armenia D; Pabo W; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Fokam J; Ndjolo A
J Antimicrob Chemother; 2022 Dec; 78(1):272-275. PubMed ID: 36411257
[TBL] [Abstract][Full Text] [Related]
15. Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
Subramanian R; Tang J; Zheng J; Lu B; Wang K; Yant SR; Stepan GJ; Mulato A; Yu H; Schroeder S; Shaik N; Singh R; Wolckenhauer S; Chester A; Tse WC; Chiu A; Rhee M; Cihlar T; Rowe W; Smith BJ
Mol Pharm; 2023 Dec; 20(12):6213-6225. PubMed ID: 37917742
[TBL] [Abstract][Full Text] [Related]
16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
Ogbuagu O; Segal-Maurer S; Ratanasuwan W; Avihingsanon A; Brinson C; Workowski K; Antinori A; Yazdanpanah Y; Trottier B; Wang H; Margot N; Dvory-Sobol H; Rhee MS; Baeten JM; Molina JM;
Lancet HIV; 2023 Aug; 10(8):e497-e505. PubMed ID: 37451297
[TBL] [Abstract][Full Text] [Related]
18. Rapid HIV-1 genotyping assay for the detection of capsid mutations.
Margot N; Naik V; Nekkalapudi A; Boopathy A; Falkard B; Callebaut C
J Med Virol; 2023 Dec; 95(12):e29292. PubMed ID: 38063404
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.
Richard N; Juntilla M; Abraha A; Demers K; Paxinos E; Galovich J; Petropoulos C; Whalen CC; Kyeyune F; Atwine D; Kityo C; Mugyenyi P; Arts EJ
AIDS Res Hum Retroviruses; 2004 Apr; 20(4):355-64. PubMed ID: 15157354
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 antiretroviral resistance: scientific principles and clinical applications.
Tang MW; Shafer RW
Drugs; 2012 Jun; 72(9):e1-25. PubMed ID: 22686620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
